GPs told to prescribe cheaper drugs to help cure NHS overspend by billions of pounds a yearPrescribing generic alternatives to branded drugs 'could save billions'Swapping could free up money for other areas of the NHS
08:29 GMT, 31 December 2012
Report: Prescribing generic alternatives to expensive branded drugs could save the NHS billions, a new study claims
Doctors could save the NHS billions of pounds a year by ditching expensive branded drugs in favour of prescribing cheaper, equally-effective alternatives, new research has found.
More than 200 million was unnecessarily spent on two types of costly statin drugs alone in the last year, despite doctors usually being advised to prescribe better value options, the study said.
The wider issue of inefficient spending on prescriptions where far cheaper generic equivalents exist is estimated to cost the NHS 1billion a year, data company Mastodon C said.
Sir Bruce Keogh, medical director of the NHS Commissioning Board, which backed the research, said it will help to 'focus minds' on reducing costs.
He said: 'Variation in prescribing habits costs the NHS millions of pounds a year.
'Transparent sharing of information will help clinicians understand whether they are over or under prescribing.
'This will focus minds in a way that will not only improve the quality of treatment for patients but also reduce cost and free up money for re-investment in other parts of the NHS.'
Mastodon C, based at The Open Data Institute, spent eight weeks working with publicly available data looking at the NHS prescribing patterns in GP practices, Clinical Commissioning Groups, and Primary Care Trusts.
The cost of an individual prescription item can vary from 81p for a generic drug, to over 20 for drugs still under licence to the pharmaceutical companies that develop them.
Francine Bennett, who carried out the data analysis said: 'We've suspected for some time that there were potential savings to be gained by looking at prescribing practices across the NHS but I wasn't prepared for the extent of the potential savings we've seen in just this analysis.
'What's important now is to work with the NHS and healthcare professionals to provide the data and analysis which can realise this potential.'
Waste: More than 200 million was unnecessarily spent on two types of costly statin drugs alone